Abstract
Lysosomal acid lipase (LAL) is an essential enzyme that hydrolyzes triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Genetic LAL mutations lead to Wolman disease (WD) and cholesteryl ester storage disease (CESD). An LAL-null (lal-/-) mouse model resembles human WD/CESD with storage of CEs and TGs in multiple organs. Human LAL (hLAL) was expressed in Nicotiana benthamiana using the GENEWARE® expression system (G-hLAL). Purified G-hLAL showed mannose receptor-dependent uptake into macrophage cell lines (J774E). Intraperitoneal injection of G-hLAL produced peak activities in plasma at 60 min and in the liver and spleen at 240 min. The t1/2 values were: ∼90 min (plasma), ∼14 h (liver), and ∼32 h (spleen), with return to baseline by ∼150 h in liver and ∼200 h in spleen. Ten injections of G-hLAL (every 3 days) into lal-/- mice produced normalization of hepatic color, decreases in hepatic cholesterol and TG contents, and diminished foamy macrophages in liver, spleen, and intestinal villi. All injected lal-/- mice developed anti-hLAL protein antibodies, but suffered no adverse events. These studies demonstrate the feasibility of using plant-expressed, recombinant hLAL for the enzyme therapy of human WD/CESD with general implications for other lysosomal storage diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1646-1657 |
| Number of pages | 12 |
| Journal | Journal of Lipid Research |
| Volume | 49 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Cholesteryl esters
- Enzyme therapy
- Macrophage
- Pharmacodynamics
- Pharmacokinetics
- Plantproduced human enzyme
- Triglyceride
ASJC Scopus subject areas
- Biochemistry
- Endocrinology
- Cell Biology
Cite this
Wolman disease/cholesteryl ester storage disease : Efficacy of plant-produced human lysosomal acid lipase in mice. / Du, Hong; Cameron, Terri L.; Garger, Stephen J.; Pogue, Gregory P.; Hamm, Lee A.; White, Earl; Hanley, Kathleen M.; Grabowski, Gregory A.
In: Journal of Lipid Research, Vol. 49, No. 8, 01.08.2008, p. 1646-1657.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Wolman disease/cholesteryl ester storage disease
T2 - Efficacy of plant-produced human lysosomal acid lipase in mice
AU - Du, Hong
AU - Cameron, Terri L.
AU - Garger, Stephen J.
AU - Pogue, Gregory P.
AU - Hamm, Lee A.
AU - White, Earl
AU - Hanley, Kathleen M.
AU - Grabowski, Gregory A.
PY - 2008/8/1
Y1 - 2008/8/1
N2 - Lysosomal acid lipase (LAL) is an essential enzyme that hydrolyzes triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Genetic LAL mutations lead to Wolman disease (WD) and cholesteryl ester storage disease (CESD). An LAL-null (lal-/-) mouse model resembles human WD/CESD with storage of CEs and TGs in multiple organs. Human LAL (hLAL) was expressed in Nicotiana benthamiana using the GENEWARE® expression system (G-hLAL). Purified G-hLAL showed mannose receptor-dependent uptake into macrophage cell lines (J774E). Intraperitoneal injection of G-hLAL produced peak activities in plasma at 60 min and in the liver and spleen at 240 min. The t1/2 values were: ∼90 min (plasma), ∼14 h (liver), and ∼32 h (spleen), with return to baseline by ∼150 h in liver and ∼200 h in spleen. Ten injections of G-hLAL (every 3 days) into lal-/- mice produced normalization of hepatic color, decreases in hepatic cholesterol and TG contents, and diminished foamy macrophages in liver, spleen, and intestinal villi. All injected lal-/- mice developed anti-hLAL protein antibodies, but suffered no adverse events. These studies demonstrate the feasibility of using plant-expressed, recombinant hLAL for the enzyme therapy of human WD/CESD with general implications for other lysosomal storage diseases.
AB - Lysosomal acid lipase (LAL) is an essential enzyme that hydrolyzes triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Genetic LAL mutations lead to Wolman disease (WD) and cholesteryl ester storage disease (CESD). An LAL-null (lal-/-) mouse model resembles human WD/CESD with storage of CEs and TGs in multiple organs. Human LAL (hLAL) was expressed in Nicotiana benthamiana using the GENEWARE® expression system (G-hLAL). Purified G-hLAL showed mannose receptor-dependent uptake into macrophage cell lines (J774E). Intraperitoneal injection of G-hLAL produced peak activities in plasma at 60 min and in the liver and spleen at 240 min. The t1/2 values were: ∼90 min (plasma), ∼14 h (liver), and ∼32 h (spleen), with return to baseline by ∼150 h in liver and ∼200 h in spleen. Ten injections of G-hLAL (every 3 days) into lal-/- mice produced normalization of hepatic color, decreases in hepatic cholesterol and TG contents, and diminished foamy macrophages in liver, spleen, and intestinal villi. All injected lal-/- mice developed anti-hLAL protein antibodies, but suffered no adverse events. These studies demonstrate the feasibility of using plant-expressed, recombinant hLAL for the enzyme therapy of human WD/CESD with general implications for other lysosomal storage diseases.
KW - Cholesteryl esters
KW - Enzyme therapy
KW - Macrophage
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Plantproduced human enzyme
KW - Triglyceride
UR - http://www.scopus.com/inward/record.url?scp=51449092035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51449092035&partnerID=8YFLogxK
U2 - 10.1194/jlr.M700482-JLR200
DO - 10.1194/jlr.M700482-JLR200
M3 - Article
C2 - 18413899
AN - SCOPUS:51449092035
VL - 49
SP - 1646
EP - 1657
JO - Journal of Lipid Research
JF - Journal of Lipid Research
SN - 0022-2275
IS - 8
ER -